
    
      This is an open-label, uncontrolled, nonrandomized, multicenter, dose-finding, single-arm,
      Phase 1 study primarily to determine the optimal dose and schedule of Fusilev to prevent or
      reduce Folotyn-related Grade 3 or higher oral mucositis.
    
  